联合肺癌与肾癌CT筛查中肾癌患病率研究
Kidney cancer (KC) screening may be facilitated by targeting individuals at a higher risk and combining with other screening programmes. Previous estimates of the prevalence of screen-detected KC are outdated and do not enable an accurate assessment in a high-risk group.…
要点
- 胸部低剂量CT筛查中肾癌患病率为0.26%(95%CI 0.15-0.41%)。
- 加做腹部平扫CT额外检出肾癌患病率为0.25%(95%CI 0.12-0.46%)。
- 结果为规划肾癌筛查研究及服务提供关键数据。
核心结论
- 在高危吸烟人群中,联合胸部低剂量CT与腹部平扫CT可检出组织学确诊的肾癌,并提供当代患病率估计。
研究设计与样本
- YKST是评估在靶向肺癌筛查(YLST)胸部低剂量CT基础上加做腹部平扫CT可行性的研究。
- YLST纳入6650例,YKST纳入4019例。
临床怎么用
- 为全国肺癌筛查推广后规划筛查检出肾癌患者的进一步检查与治疗服务提供依据。
- 为未来前瞻性肾癌筛查研究设计提供关键患病率数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Kidney cancer (KC) screening may be facilitated by targeting individuals at a higher risk and combining with other screening programmes. Previous estimates of the prevalence of screen-detected KC are outdated and do not enable an accurate assessment in a high-risk group. The Yorkshire Kidney Screening Trial (YKST) is a unique study of the feasibility of adding KC screening via an abdominal noncontrast computed tomography (CT) scan to the thoracic low-dose CT within a targeted lung cancer screening trial in ever smokers (Yorkshire Lung Screening Trial; YLST). Seventeen histologically confirmed KC cases were detected on thoracic CT in YLST (N = 6650; prevalence 0.26%; 95% confidence interval [CI] 0.15-0.41%), which has implications for future service planning to accommodate the investigation and treatment of screen-detected KC patients following the national adoption of lung cancer screening. Adding abdominal CT in YKST (n = 4019) identified an additional ten histologically confirmed KC patients (prevalence 0.25%; 95% CI 0.12-0.46%). In summary, using data from YKST, we report the first contemporary estimates of the prevalence of KC in high-risk individuals, key data required to plan future prospective screening studies.
引用
- Rossi SH, Kitt J, Godoy A, et al. Prevalence of Kidney Cancer in Attendees for Combined Lung and Kidney Cancer Screening by Computed Tomography Scanning. Eur Urol Oncol. 2025. PMID: 40835553. doi:10.1016/j.euo.2025.07.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。